Mesentech and the Importance of Bone Health

December 10th, 2020 at 4:30 PM ET

CureDuchenne, a nonprofit focused on Duchenne muscular dystrophy (DMD), has officially invested in Mesentech, Inc., through CureDuchenne Ventures. The company is in the process of developing a new therapy meant to address bone strength and density.

Join this webinar to learn more about why CureDuchenne is investing in Mesentech, why bone health is so important in the treatment of Duchenne muscular dystrophy, and how Mesentech hopes to address this complication in patients.

Click here to sign up for the webinar.